Drug Trial Radar · NCT00566891
Safety of High-dose Tirofiban During Coronary Angioplasty
Last checked: Nov 20, 2026Latest source record: Feb 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Dec 2007
Primary completion
Jul 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- S. Anna HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty.
Conditions
- Coronary Artery Disease
Interventions
tirofibanDrug
tirofiban high dose bolus 25µ/Kg
ClopidogrelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure: all cause mortalityTime frame: one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
S Anna Hospital
Catanzaro, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.